Home
This site is intended for healthcare professionals
Share

Description

This activity is supported by an independent education grant from BMS. This online education program has been designed for healthcare professionals globally, excluding the UK.

Join expert Corey Kershaw, MD, for an in-depth session on navigating antifibrotic therapy management and emerging mechanisms. This session explores strategies to proactively mitigate gastrointestinal adverse events, preserve medication persistence, and integrate new evidence into patient-tailored therapeutic plans.

This is Module Three of Four. Modules One, Two, and Four can be found here.

Session Highlights

  • Proactively manage gastrointestinal side effects through antiemetic strategies, dietary adjustments, and label-supported dose reductions before discontinuing antifibrotic therapy.
  • Utilize home monitoring tools and patient-reported outcome scores to track adherence trends and detect tolerability risks early.
  • Evaluate the expanding therapeutic landscape, including newly approved PDE4B inhibitors and emerging Phase 3 investigational agents (prostacyclin agonists and LPA1 antagonists).
  • Implement clinical decision support systems that combine eligibility verification with active monitoring prompts to guide therapy adjustments.

Target Audience

This activity is intended for pulmonologists, rheumatologists, thoracic radiologists, pathologists, pulmonology nurse practitioners, and physician assistants/associates who are central to the diagnosis and management of IPF and PPF. It is also designed for general practitioners, respiratory therapists, pharmacists, and other multidisciplinary healthcare professionals involved in the care of patients with pulmonary fibrosis.

Faculty

Dr Corey Kershaw is a Professor in the Department of Internal Medicine within the Division of Pulmonary and Critical Care Medicine at UT Southwestern. He serves as the Clinical Services Chief for the Division of Pulmonary and Critical Care Medicine, as well as the Medical Director of the Medical Intensive Care Unit and Respiratory Therapy at William P. Clements Jr. University Hospital. He has extensive clinical expertise in managing complex pulmonary conditions and critical care medicine.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr Corey Kershaw, faculty for this educational activity, has the following relevant financial relationships: Consultant, Advisor, and Speaker for Boehringer Ingelheim; Researcher for Avalyn Pharma, Bristol Myers Squibb, Daewoong Pharmaceutical, PureTech Health/Celea Therapeutics, and United Therapeutics.

The MedAll staff, program planners, and reviewers have no relevant financial relationships with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 ANCC contact hours.

Pharmacy Continuing Education

Partners designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008073-9999-26-363-H01-P

Type of Activity: Knowledge

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

PA Continuing Medical Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until September 30, 2027. PAs should only claim credit commensurate with the extent of their participation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from 1 November 2026 through to 30 September 2027.

  1. Review the objectives and disclosures
  2. Study the educational content
  3. Successfully complete activity post-test(s)
  4. Complete the activity evaluation

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the online evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has been posted.

This continuing education activity is active starting 1 November, 2026 and will expire on 30 September, 2027.

Estimated time to complete this activity: 15 Minutes

Learning objectives

By the end of this activity participants will be able to:

  • Incorporate risk stratification, high‑resolution imaging, and multidisciplinary assessment to differentiate and diagnose IPF and PPF from other ILDs early and accurately.
  • Implement multidisciplinary diagnostic and management strategies to improve timely recognition, referral, and coordinated care for patients with PF.
  • Apply knowledge of mechanisms of action and clinical evidence to treatment decisions, including patient selection and therapy timing.

Similar communities

View all

Similar events and on demand videos